11 December	Synosia Initiates Proof-of-Concept Trial of Nitisinone
	Synosia startet Proof-of-Concept-Studie von Nitisinon
03 November	Synosia Therapeutics Starts Phase IIa Trial of Nepicastat for Treatment of Post-Traumatic Stress Disorder (PTSD)
	Synosia startet Phase-IIa-Studie zur Wirkung von Nepicastat bei posttraumatischem Stresssyndrom
03 September	Synosia Therapeutics Announces Appointment of Vice President of Neuropharmacology
	Synosia Therapeutics ernennt Vice President für Neuropharmakologie
30 July	Synosia Therapeutics Initiates Study of Potential First Drug Therapy for Cocaine Dependence
29 July	Synosia Therapeutics beginnt Studie zur möglicherweise ersten medikamentösen Behandlung von Kokainabhängigkeit
24 July	US Department of Defense to Fund Trial Using Novel Compound from Synosia Therapeutics
	US-Verteidigungsministerium finanziert Studie zu neuem Wirkstoff von Synosia Therapeutics
10 June	Synosia Begins Proof-of-Mechanism Trial For Nitisinone
	Synosia startet Proof-of-Mechanism-Studie von Nitisinon
03 June	Synosia Begins Phase IIa Trial For Potential First-in-Class Treatment for Parkinson’s Disease
	Synosia startet klinische Phase-IIa-Studie über potenzielle First-in-class-Therapie für Parkinson-Krankheit
31 March	Synosia Starts Phase II Efficacy Trial For Rufinamide
	Synosia beginnt mit Wirksamkeitsstudie der Phase II für Rufinamid
04 February	Synosia Therapeutics Appoints Chief Financial Officer to New Company Headquarters in Switzerland
	Synosia Therapeutics ernennt Chief Financial Officer für die neue Firmenzentrale in der Schweiz
22 January	Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial For Epilepsy Drug Rufinamide As A Treatment For Mood Disorders
	Synosia gibt vielversprechende Ergebnisse eines Proof-of-Concept klinischen Versuchs für das Epilepsiemedikament Rufinamid bei der Behandlung von Gemütszustandsstörungen bekannt

Copyright © 2009
Synosia Therapeutics.
All rights reserved.